PD-L1ATTAC mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy

Aging (Albany NY). 2023 Mar 22;15(6):1791-1807. doi: 10.18632/aging.204598. Epub 2023 Mar 22.

Abstract

Antibodies targeting the PD-1 receptor and its ligand PD-L1 have shown impressive responses in some tumors of bad prognosis. We hypothesized that, since immunosuppressive cells might present several immune checkpoints on their surface, the selective elimination of PD-L1 expressing cells could be efficacious in enabling the activation of antitumoral immune responses. To address this question, we developed an inducible suicidal knock-in mouse allele of Pd-l1 (PD-L1ATTAC) which allows for the tracking and specific elimination of PD-L1-expressing cells in adult tissues. Consistent with our hypothesis, elimination of PD-L1 expressing cells from the mouse peritoneum increased the septic response to lipopolysaccharide (LPS), due to an exacerbated inflammatory response to the endotoxin. In addition, mice depleted of PD-L1+ cells were resistant to colon cancer peritoneal allografts, which was associated with a loss of immunosuppressive B cells and macrophages, concomitant with an increase in activated cytotoxic CD8 T cells. Collectively, these results illustrate the usefulness of PD-L1ATTAC mice for research in immunotherapy and provide genetic support to the concept of targeting PD-L1 expressing cells in cancer.

Keywords: PD-L1; cancer; immunology; inflammation; mouse models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents*
  • B7-H1 Antigen / genetics
  • CD8-Positive T-Lymphocytes
  • Cell Line, Tumor
  • Immunotherapy / methods
  • Mice
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • T-Lymphocytes, Cytotoxic
  • Tumor Microenvironment

Substances

  • B7-H1 Antigen
  • Antineoplastic Agents